http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 09:04:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Upstream+Bio+%28UPB%29+PT+Raised+to+%249+at+JPMorgan/26925573.html JPMorgan analyst Tessa Romero raised the price target on Upstream Bio (NASDAQ: UPB) to $9.00 (from $8.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Upstream+Bio+%28UPB%29+PT+Raised+to+%249+at+JPMorgan/26925573.html Fri, 14 Aug 2026 09:04:33 -0400 UPB http://www.streetinsider.com/Analyst+PT+Change/Upstream+Bio+%28UPB%29+PT+Lowered+to+%2425+at+Truist+Securities/26908866.html Truist Securities analyst Danielle Brill lowered the price target on Upstream Bio (NASDAQ: UPB) to $25.00 (from $43.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Upstream+Bio+%28UPB%29+PT+Lowered+to+%2425+at+Truist+Securities/26908866.html Wed, 12 Aug 2026 07:16:24 -0400 UPB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+NORGES+BANK/26908536.html si-local-file:///var/storage/secattach/20260812/26908536.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+NORGES+BANK/26908536.html Wed, 12 Aug 2026 06:37:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+NORGES+BANK/26908536.html si-local-file:///var/storage/secattach/20260812/26908536.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+NORGES+BANK/26908536.html Wed, 12 Aug 2026 06:37:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+30/26901306.html si-local-file:///var/storage/secattach/20260811/26901306.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+30/26901306.html Tue, 11 Aug 2026 07:11:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+30/26901306.html si-local-file:///var/storage/secattach/20260811/26901306.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+30/26901306.html Tue, 11 Aug 2026 07:11:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Aug+11/26901269.html si-local-file:///var/storage/secattach/20260811/26901269.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Aug+11/26901269.html Tue, 11 Aug 2026 07:05:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Aug+11/26901269.html si-local-file:///var/storage/secattach/20260811/26901269.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Aug+11/26901269.html Tue, 11 Aug 2026 07:05:00 -0400 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Press+Releases/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html <p align="center"><em>– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –</em></p> <p align="center"><em>– Completed enrollment in Phase 2 trial in COPD; data expected in the second half of 2027 –</em></p> <p align="center"><em>– Clinical data presentations continue to emphasize differentiated profile of verekitug in multiple indications –</em></p> <p>WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_c8uc8qHoe3_Vra8v0DYSoeOa5oIGWicMsLXFztewoifCUZZClw0sDP6Z2lw7-1U1rqPHH3oWXHqNBGn6cgoiRoQqMvmeJDnJ5AVbwkPyHY=" rel="nofollow" target="_blank">Upstream Bio, Inc.</a> (Nasdaq: UPB), a clinical-stage company developing treatments for severe http://www.streetinsider.com/Globe+Newswire/Upstream+Bio+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Continued+Progress/26901112.html Tue, 11 Aug 2026 07:00:00 -0400 A.06822034 A.50201579 O.12524441 O.20026344 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26841321.html si-local-file:///var/storage/secattach/20260730/26841321.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26841321.html Thu, 30 Jul 2026 11:20:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26841321.html si-local-file:///var/storage/secattach/20260730/26841321.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Upstream+Bio%2C+Inc.+++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26841321.html Thu, 30 Jul 2026 11:20:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Deykin+Aaron/26659802.html si-local-file:///var/storage/secattach/20260617/26659802.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Deykin+Aaron/26659802.html Wed, 17 Jun 2026 16:05:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Deykin+Aaron/26659802.html si-local-file:///var/storage/secattach/20260617/26659802.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Deykin+Aaron/26659802.html Wed, 17 Jun 2026 16:05:00 -0400 O.68988411 UPB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Ambrose+Allison/26659804.html si-local-file:///var/storage/secattach/20260617/26659804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Upstream+Bio%2C+Inc.++++++++For%3A+Jun+16++Filed+by%3A+Ambrose+Allison/26659804.html Wed, 17 Jun 2026 16:05:00 -0400 O.68988411 UPB